Medical Devices

63 tickers in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
Zimmer Biomet Holdings, Inc.
ZBH·Healthcare
A ★★★★Buy
Current$105.59
Target$117.65
Return+11.4%
Nov 7, 2026

Zimmer Biomet offers durable orthopedic demand, strong cash generation, and recovery potential at modest forward earnings multiples, but knee weakness, acquisition leverage, and uncertain robotics returns constrain upside.

Score
79
Merit Medical Systems, Inc.
MMSI·Healthcare
A ★★★★Buy
Current$86.24
Target$102.30
Return+18.6%
Nov 1, 2026

Merit Medical offers durable procedure-driven growth, improving margins, and a discount to historical valuation levels, but competition, acquisition execution, and demanding cash flow expectations remain key risks.

Score
79
Zoetis Inc.
ZTS·Healthcare
A ★★★★Buy
Current$79.40
Target$99.75
Return+25.6%
Nov 8, 2026

Zoetis offers a potentially attractive recovery opportunity through its leading animal-health franchise, strong cash generation, and compressed valuation, although U.S. veterinary demand weakness and dermatology competition threaten future earnings growth.

Score
78
IDEXX Laboratories, Inc.
IDXX·Healthcare
A ★★★★Buy
Current$698.55
Target$653.60
Return-6.4%
Nov 5, 2026

IDEXX combines a deeply integrated veterinary diagnostics ecosystem with exceptional cash generation and recurring revenue growth, but its substantial valuation premium leaves investors exposed to slower testing demand or earnings growth.

Score
78
Danaher Corporation
DHR·Healthcare
A ★★★★Buy
Current$229.75
Target$243.10
Return+5.8%
Oct 23, 2026

Danaher's high-switching-cost life sciences and diagnostics franchises can compound cash flow as bioprocessing demand recovers, but acquisition-related leverage and a demanding valuation limit its margin of safety.

Score
78
Mettler-Toledo International Inc.
MTD·Healthcare
A ★★★★Buy
Current$1,722.15
Target$1,590.00
Return-7.7%
Nov 8, 2026

Mettler-Toledo combines exceptional capital efficiency, durable precision-instrument franchises, and consistent cash generation, but its premium valuation requires sustained earnings growth and offers limited downside protection.

Score
77
Fresenius Medical Care AG
FMS·Healthcare
A ★★★★Buy
Current$23.66
Target$26.40
Return+11.6%
Nov 6, 2026

Fresenius Medical Care offers durable dialysis demand, strong free cash flow, and buyback-supported earnings recovery at a modest valuation, although reimbursement pressure, weak treatment volumes, and restructuring execution remain significant risks.

Score
77
Envista Holdings Corporation
NVST·Healthcare
A ★★★★Buy
Current$25.17
Target$28.00
Return+11.2%
Nov 7, 2026

Envista offers a dental-products turnaround supported by improving margins, resilient cash generation, and reasonable valuation, although elective-procedure cyclicality and intense competition could limit the recovery.

Score
76
OSI Systems, Inc.
OSIS·Technology
A ★★★★Buy
Current$199.44
Target$217.74
Return+9.2%
Nov 1, 2026

OSI Systems combines specialized security technology, record backlog, and improving cash generation with attractive long-term demand, although geopolitical delivery delays and working-capital volatility could limit earnings realization.

Score
76
STERIS plc
STE·Healthcare
A ★★★★Buy
Current$252.30
Target$272.80
Return+8.1%
Nov 7, 2026

STERIS combines recurring infection-prevention revenue, specialized sterilization infrastructure, and durable healthcare demand, but its premium cash-flow valuation and debt-financed Xodus acquisition constrain near-term upside.

Score
75
Henry Schein, Inc.
HSIC·Healthcare
A ★★★★Buy
Current$85.31
Target$98.60
Return+15.6%
Nov 6, 2026

Henry Schein offers a healthcare distribution earnings-recovery opportunity supported by share gains, margin expansion, and buybacks, although elevated leverage and modest returns on invested capital constrain its upside.

Score
75
Fortive Corporation
FTV·Technology
A ★★★★Buy
Current$65.23
Target$69.51
Return+6.6%
Oct 31, 2026

Fortive combines durable industrial technology franchises, strong free cash flow, and aggressive buybacks with improving earnings momentum, although healthcare margin pressure and a relatively full valuation constrain near-term upside.

Score
75